Trial Profile
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Activity of MetMAb, a Monovalent Antagonist Antibody to the Receptor Met, Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Nov 2018
Price :
$35
*
At a glance
- Drugs Onartuzumab (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Genentech
- 18 Aug 2011 New source identified and integrated (M.D. Anderson Cancer Center).
- 07 Jul 2011 Final efficacy results presented at the 14th World Conference on Lung Cancer.
- 07 Jun 2011 Tolerability and tumour growth rate analyses presented at the 47th Annual Meeting of the American Society of Clinical Oncology.